- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (Nasdaq:ARWR) announced today that Dr. Thomas Schluep, Chief Scientific Officer of Insert Therapeutics, a majority owned subsidiary of Arrowhead, will present at the Nanotech for Investors Summit at the Nano Science and Technology Institute 2007 Conference on May 21, 2007 in Santa Clara, California. Dr. Schluep's presentation, entitled "Insert Therapeutics Product Development Update," will highlight Insert's technical and clinical progress in using its proprietary polymeric transport system, CyclosertTM, to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Insert's lead drug candidate, a combination of its linear, cyclodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006.
Dr. Schluep is responsible for Insert's drug discovery and development programs. Prior to joining Insert in 2004, Dr. Schluep was in charge of the non-viral gene therapy program at Canji, Inc., a wholly owned subsidiary of Schering-Plough. While at Canji, he held multiple positions of increasing responsibility in the development, manufacture, and analytical testing of non-viral and adenoviral gene therapy vectors. A constant interest of Dr. Schluep has been to understand the role nanotechnology can play in enhancing the efficacy and therapeutic index of a wide variety of therapeutics. He holds a Sc.D. in Process Engineering and an MS in Biotechnology, both from the Swiss Federal Institute of Technology in Zurich, Switzerland.
About Arrowhead Research Corporation
Arrowhead Research Corporation ( http://www.arrowheadresearch.com ) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
About Insert Therapeutics
Insert Therapeutics, Inc. ( http://www.insertt.com ), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert’s affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Arrowhead Research Corporation
Virginia E. Dadey, 212-541-3707
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
National Conference on Nanomaterials, (NCN-2017) April 21st, 2017
Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other – not merely making contact April 21st, 2017
Forge Nano 2017: 1st Quarter Media Update April 20th, 2017